
Opinion|Videos|February 7, 2025
Safety Profile of New Therapies
Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
- Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
- Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
2
How European clinicians are revolutionizing retina care
3
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
4
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management
5









































